Tissue Engineered Skin Substitutes Market - Latest Trends & Insights 2023

In 2014, the global tissue engineered skin substitutes market was recorded at US$0.9 bn. In what is considered to be a meteoric rise, this market will be valued at US$3.8 bn by the end of 2023. According to the latest research report published by market intelligence powerhouse Transparency Market Research, the global tissue engineered skin substitutes market is expanding at a CAGR of 17.2% within a forecast period of 2015 to 2023. The report is titled “Tissue Engineered Skin Substitutes Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2015 - 2023” and is available on the company website.

One of the greater markets that has emerged from bioengineering is the global tissue engineered skin substitutes market, which comprises treatments and solutions for burns, lacerations, vascular ulcers, and diabetic ulcers. These skin substitutes are generated from either human tissue or non-human tissue, or a combination of both. The common constituents of skin substitutes are generated from tissue or skin. They include a combination of bioengineered cells and extracellular matrices.

According to the report, the key driver for the global tissue engineered skin substitutes market is the increasing number of patients suffering from diabetes and vascular ulcers. Both types of patients form the largest pool of patients in need of bioengineering solutions. Another factor propelling the global tissue engineered skin substitutes market is the growing percentage of the elderly. The currently high geriatric population, along with the high need for minimally invasive procedures, is building this market for a much faster growth rate than previously expected.

Another regional driver for the global tissue engineered skin substitutes market in general is the increasingly popular concept of medical tourism. Patients from developed nations are turning to Asia Pacific and Latin America for cheaper medical solutions, including the use of tissue engineered skin substitutes. This applies especially to Asia Pacific, which is why the Asia Pacific tissue engineered skin substitutes market is likely to exhibit the fastest growth rate in the given forecast period. This region is further aided by rapidly developing healthcare infrastructure and the increase in medical expenditures by patients in the region.

A major restraint to the global tissue engineered skin substitutes market, however, is the lack of feasible reimbursement policies.

The report offers a segmented perspective on the global tissue engineered skin substitutes market to create a highly detailed analysis for its readers. One of the segmentation criteria involves the types of skin substitutes in this market: cellular autologous, cellular allogenic, acellular, and others. This market was led by the segment of acellular skin substitutes in 2014 and the report expects this segment to grow at the fastest CAGR in the given forecast period. Acellular skin substitutes are highly preferred due to their use in implant-based skin surgery.

Download exclusive Sample of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=3854

On the basis of applications, the global tissue engineered skin substitutes market is segmented into diabetic and vascular ulcers, burn injuries, and others. The largest segment in the market in 2014 was diabetic and vascular ulcers. TMR analysts expect this segment to continue leading the market throughout the forecast period, within which it will display the fastest growth rate in applications. This segment, as well as the overall tissue engineered skin substitutes market, is therefore being propelled by a growing number of patients suffering from diabetes.

The key players in the global tissue engineered skin substitutes market are Integra LifeSciences Corporation, Mölnlycke Health, Acelity, L.P., Inc., Medtronic, BSN Medical, and 3M Health Care.

Ebola Drug and Vaccine Market - Worldwide Market Shares, Strategies, and Forecasts 2016 to 2024

The rising threat of a global Ebola pandemic is the major driver for the global Ebola drug and vaccines market, according to a new report from Transparency Market Research. The report, titled ‘Ebola Drug and Vaccine Market - Global Industry Analysis, Size, Share, Growth, Trends & Forecasts 2016 – 2024,’ presents a solid outline of the historical development of the market, in addition to comprehensive information about the market’s present condition. TMR analysts have further presented reliable predictions regarding the market’s development in the coming years based on insights into the market’s development pattern.

Ebola is a viral disease causing both external and internal bleeding, fever, muscular pain, headaches, vomiting, and notable impairment of liver and kidney functions. Like many viral diseases, Ebola can spread through direct contact with the body fluids of an affected human or animal. The Ebola drug and vaccines market came into the global spotlight after the epidemic in West Africa in late 2013. Since then, governments in many countries where Ebola has spread have taken steps to fund extensive research into treating the disease. Continued government support is crucial for the Ebola drug and vaccines market in the coming years.

The lack of an effective cure for Ebola has driven investment into the field, with the unknown variables about the Ebola virus necessitating extensive research to come up with treatments and disease management plans. This has also made research into Ebola drugs and vaccines financially lucrative for healthcare industry players due to the possibility of coming up with different containment and management solutions targeted at different aspects of the disease.

The government support to the Ebola drug and vaccines market has been amplified by the spread of the disease to the developed world. This has brought the matter to the attention of the much better equipped healthcare sector in the developed world, where long-term research into Ebola therapeutics is economically feasible. This has notably boosted research into the etiology and treatment of the disease in recent years. The prevailing risk of further outbreaks due to the increasing ease of getting in and out of the region where Ebola originated is likely to ensure steady funding for research into Ebola drugs and vaccines in the coming years.

View exclusive Global strategic Business Report : http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=12476

Geographically, North America is the leading contributor to the global Ebola drug and vaccines market. The advanced healthcare research scenario in North America is responsible for the leading share of the regional segment, with U.S. healthcare industry players having among the most comprehensive operations in the field of Ebola research.

The key companies in the global Ebola drug and vaccines market are Serepata Therapeutics, NewLink Genetics Corp., Tekmira Pharmaceuticals, BioCryst Pharmaceutical Inc., and Mapp Biopharmaceutical. The report presents detailed information about the market operations of these companies in order to derive vital insights into the competitive landscape of the Ebola drug and vaccines market.

Tissue Engineered Skin Substitutes Market - Latest Trends & Insights 2023

The global market for tissue engineered skin substitutes is mostly consolidated as four companies currently maintain a strong hold over revenue shares in market value. The top three players in 2014 were Acelity, Smith & Nephew, and Molnlycke. Their collective share in market value in 2014 was 51.4%. Most commonly, the key providers of tissue engineered skin substitutes offer a wide product profile, invest heavily in research and development to stay ahead of the pack, and possess strong marketing processes and distribution networks.

As a result, although the collective share of regional tissue engineered skin substitute providers is quite large, the reach of key players coupled with the strict set of guidelines governing the release of any product in the market, have created only a moderate threat level from new entrants.

The global market for tissue engineered skin substitutes is expected to generate revenue at a highly positive CAGR of 17.2% within a forecast period from 2015 to 2023. This market is expected to generate a revenue of US$1.2 bn by the end of 2016, and US$3.87 bn by 2023.

Medical Tourism Creates Wide Revenue Stream for Tissue Engineered Skin Substitute Providers

“Medical tourism, as an industry, is already a multi-billion dollar one and is showing an annual growth rate in double digits,” states a TMR analyst. “The use of tissue engineered skin substitutes in developed nations is not only growing in numbers, but is also over-expensive and unaffordable for some without a feasible reimbursement policy. As a result, a large number of patients seeking tissue engineered skin substitute treatment are doing so through medical tourism.”

Nations such as Thailand, Malaysia, India, and Singapore are at the forefront of medical tourism and can offer state of the art technologies for tissue engineered skin substitute treatment at a much cheaper rate than that from North America or Europe.

Additionally, medspas, or medical clinics that include a day spa, are a highly preferred place for treatment and healing by the elderly, especially for cases such as treatment of ulcers and venous diseases. Their higher number in developing economies is another factor driving the scope of medical tourism in the tissue engineered skin substitute market.

Cost Effectiveness of Tissue Engineered Skin Substitutes Reduced by Intense Competition

The presence of a large number of local players adds a major layer of restraint to the globally prominent ones for the tissue engineered skin substitutes market. Local players can offer products at a much cheaper cost, thereby forcing key players to match their prices and reduce profit margins.

The profits that can be channeled into research and development, therefore, decrease, slowing down the overall growth of the market for tissue engineered skin substitutes. This is more prevalent in developing economies, where the disparity in costs between local and global tissue engineered skin substitute players is quite high.

Download Free exclusive Sample of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=3854

Asia Pacific to Scale up Demand for Tissue Engineered Skin Substitutes

Owing to a growing population and a rapidly improving healthcare infrastructure in terms of quality and outreach, Asia Pacific is expected to show the fastest growth rate for tissue engineered skin substitutes. It is expected to progress at a CAGR of 18.3% within the forecast period from 2015 to 2023.

Acellular skin substitutes have not only been the dominant type of tissue engineered skin substitutes, but have registered promising growth. From 2015 to 2023, this segment is expected to progress at a CAGR of 17.8%. The leading application for tissue engineered skin substitutes is to treat ulcers. This application segment is expected to progress at a CAGR of 17.5% from 2015 to 2023.

The information presented in this review is based on a Transparency Market Research report, titled, “Tissue Engineered Skin Substitutes Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2015 - 2023.”